Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 1,609 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genenta Science SPA | GNTA | NASDAQ | Depository Receipt |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 1.69% | 3.00 | 09:33:38 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.81 | 2.81 | 3.04 | 2.95 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 20 | 1,609 | 2.98 | 4,803 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:57:09 | 30 | 3.04 | USD |
Genenta Science SPA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 54.65M | 18.22M | - | 1.19M | -7.68M | -0.42 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Genenta Science
| Date | Time | Source | Heading |
|---|---|---|---|
| 2/12/2024 | 15:05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/08/2024 | 04:00 | GlobeNewswire Inc. | Genenta Demonstrated Reprogramming of the Tumor.. |
| 10/20/2023 | 15:15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 9/06/2023 | 06:00 | GlobeNewswire Inc. | Genenta to Present at Upcoming Scientific and Investor.. |
| 7/28/2023 | 02:00 | GlobeNewswire Inc. | Genenta Announces Ongoing Clinical Trial Progress and.. |
| 6/29/2023 | 06:00 | GlobeNewswire Inc. | The European Commission Grants Orphan Drug Designation to.. |
| 5/16/2023 | 06:00 | GlobeNewswire Inc. | Genenta to Provide Update on Lead Product Temferon™ |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
GNTA Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. |
